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Abstract
Introduction: Immune checkpoint inhibitors can lead to thyroid dysfunction. However, the 
understanding of the clinical phenotype of ICI-induced thyroid dysfunction in the real-
world population is limited. The purpose of this study was to characterise the clinical 
patterns of dysfunction and evaluate the demographic, biochemical and immunological 
features associated with this patient cohort.
Materials and methods: To characterise the longitudinal clinical course of thyroid 
dysfunction in patients from a single, UK regional cancer centre, a retrospective review 
of patients was conducted. Inclusion criteria included all patients treated with antiPD-1 
checkpoint inhibitors (ICI), either as monotherapy (pembrolizumab/nivolumab) or in 
combination with a CTLA-4 inhibitor (ipilimumab). Patterns of toxicity were evaluated 
together with assessment of antibody titres.
Results: Over 16 months, thyroid dysfunction was seen in 13/90 and 3/13 patients treated 
with anti-PD1 monotherapy and in combination with ipilimumab, respectively. Patients 
either developed hyperthyroidism followed by hypothyroidism (12/16) or de novo 
hypothyroidism (4/16). Most patients were female (n = 11). All patients required thyroid 
replacement therapy. There was no relationship between clinical pattern of dysfunction 
and the presence of thyroid autoantibodies.
Conclusions: There are two distinct patterns of thyroid dysfunction in ICI-treated patients. 
Patients with thyroiditis develop subsequent hypothyroidism in the vast majority of cases. 
The potential benefit from steroids or other therapy to manage the hyperthyroid phase 
remains unclear. Early detection of these patients through appropriate monitoring will 
improve clinical management and early hormone replacement, reducing the symptomatic 
burden of hypothyroidism.
Introduction
Oncological immune checkpoint inhibitors (ICI) are 
transforming oncological practice (1, 2, 3). The first ICI, 
ipilimumab (Yervoy®), a CTLA-4 inhibitor, was used 
exclusively in metastatic malignant melanoma post-
licensing (3, 4). Subsequently, the PD-1 ICIs, nivolumab 
(Opidivo®) and pembrolizumab (Keytruda®), have led to 
increased efficacy and, in general, a superior safety profile 
compared to CTLA-4 inhibitors (5). Efficacy can be further 
improved by combining nivolumab and ipilimumab (1, 
2, 6). ICIs are now used in the mainstream treatment of 
metastatic melanoma, non-small cell lung cancer renal cell 
carcinoma, urothelial and head and neck cancers (7, 8). 
Nivolumab and pembrolizumab also hold global licences 
for additional indications including gastro-oesophageal 
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adenocarcinoma, classical Hodgkin’s lymphoma and 
malignancies expressing microsatellite instability.
The use of ICIs has led to a range of novel adverse drug 
reactions (1) (hereafter called immune related adverse 
events (irAE)) which resemble endogenous autoimmune 
disease (9). Rash and colitis are the predominant irAEs 
caused by ipilimumab. The predominant endocrine 
irAE induced by ipilimumab is hypophysitis, occurring 
in 4–13% of patients (1, 2, 4). Thyroid dysfunction is 
witnessed in 1–5% of patients (1, 2, 4).
In the oncology setting, adverse events are graded 
using the Common Terminology Criteria for Adverse 
Events (CTCAE) criteria (10) from 1 to 5, with grade 1 
representing mild toxicity and 5 representing death as 
a result of toxicity. As monotherapy, anti-PD-1 agents 
induce grade 3/4 (severe/life-threatening) irAEs in 15% 
of patients (1, 7). The incidence of severe irAEs increases 
further with combination checkpoint blockade with grade 
3/4 irAEs occurring in 58–68% of patients (1, 2). The 
incidence of thyroid dysfunction is increased with PD-1 
inhibitor therapy when compared with ipilimumab (6, 9, 
10). While the majority of irAEs are treatable and reversible 
with corticosteroid containing immunosuppression, the 
endocrinopathies appear to be irreversible and, in the 
majority of cases, require lifelong replacement therapy (11).
Thyroid dysfunction reported within metastatic 
malignant melanoma clinical trials included both 
hyperthyroidism and hypothyroidism (Supplementary 
Table 1, see section on supplementary materials given at 
the end of this article) but the clinical and biochemical 
manifestations were not detailed. Radioisotope scanning 
of patients experiencing thyroid dysfunction has suggested 
a cytotoxic mechanism rather than autoantibody driven 
disease. Indeed, the association with autoantibodies 
remains unclear with variable results between studies 
(12, 13). Active management of ICI-induced thyroiditis is 
required despite the fact that the acute toxicity is of lower 
grade than other irAEs. It is also generally permanent, 
with only limited reports of recovery (14). No clinical 
predictors of thyroid toxicity following ICI therapy have 
been identified, and baseline TSH does not appear to 
predict the occurrence of thyroiditis (12). ICI treatment 
duration may be positively correlated with the occurrence 
of thyroiditis (15).
The aim of our paper was to characterise the 
longitudinal clinical course of thyroid dysfunction 
in patients from a single, UK regional cancer centre 
to determine if there is a characteristic pattern of 
biochemical abnormality, the proportion of patients 
experiencing clinically significant symptoms and the 
relationship of autoantibodies with biochemical change. 
Furthermore, we examined whether ypothyroidism was 
indeed the predominant manifestation of ICI-induced 
thyroid toxicity.
Materials and methods
A retrospective review of case notes of patients 
treated with anti-PD-1 ICIs for metastatic melanoma 
over a 16-month treatment period was undertaken 
at the Clatterbridge Cancer Centre, UK. The review 
included all patients treated with anti-PD1 ICI, either 
as monotherapy (pembrolizumab/nivolumab) or 
nivolumab in combination with ipilimumab, an anti-
CTLA4 ICI. Patient electronic records were reviewed to 
identify patients with thyroid dysfunction defined as the 
presence of deranged thyroid function denoted by a T4 
level outside the standard reference range. Patients were 
considered to have had thyroid dysfunction irrespective 
of their clinical symptoms (i.e. clinical and subclinical 
biochemical disturbance). The presentation, clinical 
course (biochemical and symptomatic) and emerging 
longitudinal biochemical patterns of toxicity were 
evaluated to determine the presence of specific clinical 
trajectories within the cohort. All patients found to have 
a single abnormal T4 level were evaluated to determine if 
the changes were transient or led to established thyroid 
dysfunction. Within this cohort, all patients found to 
have a single abnormal reading went on to develop either 
HH or DN. Thyroid autoantibody titres (thyroid receptor 
antibody (TRAb), anti-thyroid peroxidase (TPO)) were also 
determined. Patients who had a diagnosis of pre-existing 
thyroid disorders (either hyper- or hypothyroidism) were 
excluded from the patient cohort. Aside from T4, if patients 
were found to have baseline biochemical parameters 
outside the normal ranges (eg TSH) but were subclinical 
and had no formal diagnosis of thyroid dysfunction, they 
were included in the cohort.
The local reference ranges for thyroid function tests 
were as follows: free T4 11.5–22.7 pmol/L; TSH 0.3–5.5 
mU/L; free T3 3.1–7 pmol/L; TRAb 0.0–1.8 U/L and 
anti-TPO 0.0–33.9 IU/mL.
Patient sampling and processing
As part of the standard clinical management of ICI 
administration at the Clatterbridge Cancer Centre, 
all patients’ thyroid status (TSH, T4) is assessed at baseline. 
Recurrent testing of TSH (with T4 and T3 evaluated if 
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TSH is found to be outside the reference range) is then 
performed on a 3-weekly basis, alongside a standardised 
biochemical panel including full blood count, urea and 
electrolytes, liver function tests, cortisol and random 
glucose levels. Patients experiencing thyroid dysfunction 
also undergo thyroid autoantibody assessment. Anti-
thyroglobulin antibodies are not analysed in routine 
clinical practice, and therefore all living patients with 
thyroid dysfunction during ICI therapy were approached 
to donate a blood sample in line with the Clatterbridge 
Biobank ethical approval. Informed consent was obtained. 
The presence of anti-Tg antibodies was analysed by ELISA 
using a human anti-thyroglobulin ELISA kit (ab178631) 
on serum isolated from donated samples.
Data analysis
Time to event is presented as median durations with 
associated interquartile ranges. Descriptive statistics are 
presented as means with 95% CIs. Comparisons between 
groups have utilised Mann–Whitney and Kruskal3-weekly 
basisWallis analyses, as appropriate. All statistical tests 
utilised a significance value of P < 0.05.
Results
Patient demographics
Over the 16-month period, between February 2016 and 
May 2017, a total of 103 patients were treated with PD-1 
ICIs for metastatic melanoma in the palliative setting. 
Ninety patients received monotherapy, while 13 received 
combination treatment. Thyroid dysfunction was 
observed in 16/103 of patients; 13 out of the 90 received 
monotherapy and 3/13 received combination therapy. All 
patients within the cohort were Caucasian (Table 1). For 
all other patients, thyroid function remained within the 
normal range throughout therapy.
Patterns of thyroid dysfunction and treatment
Two clear patterns of thyroid dysfunction were 
identified (Table 1): hyperthyroidism followed by 






Hyperthyroidism followed by 
hypothyroidism (HH)
De novo  
hypothyroidism (DN)
Number of patients (n = 16) 13 3 12 4 
Gender
 Male (M) 4 1 5 0
 Female (F) 9 2 7 4 












 Mean 58 57 56 70.5
 Range 29–74 46–64 29–64 48–89
Ethnicitya
 White British 13/13 2/3 11/12 4/4
 White Polish 0/13 1/3 1/12 0/4
 Other 0 /13 0 0/12 0/4
Melanoma subtype
 Cutaneous 11/13 2/3 8/12 4/4
 Uveal 1/13 1/3 3/12 0/4
 Anal 1/13 0/3 1/12 0/4
Number of metastatic sites
 1 4/13 1 (33.3%) 3/12 1/4
 2 6/13 1 (33.3%) 6/12 2/4
 ≥3 3/13 1 (33.3%) 3/12 1 /4
Line of treatment
 1 5/13 1/3 5 /12 3/4
 2 6/13 1/3 6/12 0/4
 3 2/13 1/3 1/12 1/4
Type of treatment
 Monotherapy 13/13 3/3 9/12 4/4
 Combination therapy 0/13 0/3 3/12 0/4
aLikely to reflect the ethic mix of the local population.
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hypothyroidism (HH) in 12/16 of cases and de novo (DN) 
hypothyroidism in 4/16 of cases.
With the HH pattern, there was an initial period 
of, minimally symptomatic or asymptomatic, 
hyperthyroidism followed by a decline in T4 and 
subsequent hypothyroidism. Where TSH was found to 
be low, both T4 and T3 were measured, but there were 
no cases of T3 elevation in the presence of a T4 within 
the normal range. The HH pattern was seen in 9/13 of 
patients receiving monotherapy and in all patients 
receiving combination therapy (Fig. 1A, B and C). The 
median time to onset was 9 weeks (range 6–27; IQR 3) 
and 3 weeks (range 3–6; IQR 3) with monotherapy ICI 
and combination therapy, respectively. The hyperthyroid 
phase duration was 9 weeks (range 3–15; IQR 6) in patients 
receiving monotherapy and universally 6 weeks (range 6; 
IQR 0 as) in those receiving combination therapy. The time 
to onset of thyroid dysfunction from the commencement 
of ICI therapy was significantly longer (P = 0.02) in 
the monotherapy group, but the duration of the 
hyperthyroid phase did not differ between monotherapy 
and combination therapy patients (P = 0.25). The T4 peak 
was 39.3 pmol/L (95% CI 32.7–45.9 pmol/L) and lasted 
6–21 days. All cases were associated with a trough TSH 
of <0.1 mU/L. The mean trough T4 seen prior to thyroid 
replacement in the pooled analysis was 6.6 pmol/L 
(95% CI 4.9–8.3 pmol/L), associated with a mean peak 
TSH of 53.2 mU/L (95% CI 25.6–80.8 mU/L).
The second pattern of thyroid dysfunction, DN 
hypothyroidism, did not have a preceding hyperthyroid 
phase (Fig. 2A and B). However, there were two patients 
who had TSH levels <0.3 mU/L but with normal T3/T4 
during therapy. TSH levels were within the normal range 
(4.38 mU/L; 3.63 mU/L) at baseline in these two patients. 
All patients with DN hypothyroidism were asymptomatic 
prior to the detection of the hypothyroid state, apart 
from grade 1 fatigue in four patients. The median time to 
development of thyroid dysfunction after monotherapy 
ICI was 12 weeks (range 6–18 weeks; IQR 6 weeks). The 
trough T4 prior to commencement of levothyroxine was 
4.45 pmol/L (95% CI 0.4–8.5 pmol/L), with an associated 
peak TSH of 69.0 mU/L (95% CI 44.7–93.2 mU/L).
Only one patient developed clinical symptoms and 
had the highest observed T4 (T4 60 pmol/L) level and 
was the only patient to require symptomatic treatment 
with β-blockade. None of the other patients displayed any 
classic clinical symptoms of either hyper- or hypothyroid 
dysfunction. Clinical examination did not reveal any 
signs of thyroid disease including goitre, exophthalmos, 
pretibial myxoedema or proximal myopathy.
The hyperthyroid phase in HH spontaneously 
terminated in all patients without pharmacological 
intervention with thioamides. Patients were monitored 
for resolution of their thyroid function, but no 
recovery was seen. All patients required long-term 
levothyroxine replacement. Following the management 
Figure 1
Changes in TSH (black) and T4 (grey) with the 
thyroid dysfunction characterised by an initial 
phase of hyperthyroidism followed by 
hypothyroidism (HH). (A) Changes in thyroid 
hormones over time. (B) Pattern of T4 changes 
from the point of dysfunction in patients receiving 
monotherapy immunotherapy. (C) Pattern of T4 
changes from the point of dysfunction in patients 
receiving combination immunotherapy with 
ipilimumab and nivolumab.
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of thyroid dysfunction, all patients continued with ICI 
immunotherapy. However, thyroid dysfunction did result 
in a treatment break with ICIs, the longest of which was 
for 20 weeks (mean 2; range 0–20).
Associations with thyroid dysfunction
Gender
Females were more commonly affected than males, with 
11/16 being women (P = 0.04), but most notably all patients 
developing DN hypothyroidism without a preceding 
hyperthyroid phase were female in this series. Of note, 
within the total treated population, 57/103 were male 
and 46/103 were female, thus the female predominance 
of thyroid dysfunction did not reflect the gender split of 
the treated population overall.
Pre-treatment TSH levels
The pre-treatment mean TSH level in the DN group 
(5.77 mU/L; 95% CI 2.45–9.09 mU/L) was higher 
(P = 0.009) than in the HH group (2.49 mU/L; 95% CI 
1.78–3.22 mU/L) (Supplementary Fig. 1). Patients 
with a known diagnosis of thyroid dysfunction were 
excluded from evaluation but we did include patients 
(n = 2) with sub-clinically elevated TSH levels at 
baseline. Both of these patients went on to develop DN 
hypothyroidism without a hyperthyroid phase. It is 
unclear as to whether these patients would have gone 
on to develop clinical hypothyroidism with depressed 
T3/T4 levels in the absence of checkpoint blockade. 
All the patients included in this analysis had normal 
T4/T3 levels at baseline prior to treatment 
with immunotherapy.
Thyroid autoantibodies
Of the 16 patients identified to have thyroid dysfunction, 
12 had thyroid autoantibodies assessed. Five out of the 
12 were found to have positive thyroid antibodies (anti-
TPO, anti-Tg and anti-TRAb). One patient developed HH 
on pembrolizumab monotherapy and had a positive anti-
TPO titre of 60.43 IU/mL. A second patient developed 
HH on combination immunotherapy and had a positive 
anti-TPO titre of 505 IU/mL and was anti-Tg Elisa positive 
with a concentration of 275.12 U/mL. A third patient who 
developed DN on pembrolizumab monotherapy had a 
positive anti-TPO titre of 183 IU/mL and a TRAb titre of 
3.5 U/L despite being hypothyroid and requiring 
levothyroxine. A further two patients who both 
developed the HH pattern of dysfunction, one receiving 
pembrolizumab monotherapy and the other combination 
ICI, had positive anti-Tg antibodies with titres of 
208.43 U/mL and 117.95 U/mL, respectively. TRAb and 
anti-TPO antibodies were not detected in these patients. 
The remaining seven patients had negative TRAb, anti-TPO 
and anti-Tg antibodies. There was no correlation with the 
clinical pattern.
Figure 2
Changes of TSH (black) and T4 (grey) changes with 
the de novo (DN) pattern of thyroid dysfunction. 
(A) Changes in thyroid hormones over time.  
(B) Pattern of T4 changes from the point of 
dysfunction in patients receiving monotherapy 
immunotherapy.
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In this report of patients with metastatic malignant 
melanoma receiving ICI therapy, we have undertaken 
longitudinal characterisation of patients who developed 
thyroid dysfunction and shown two clinical patterns 
of thyroid dysfunction: hyperthyroidism followed 
by hypothyroidism and de novo development of 
hypothyroidism. We also showed an association with 
gender and variable presence of autoantibodies. A recent 
systematic review of 38 randomised clinical trials showed 
that the risk of thyroid dysfunction was highest with 
combination therapy, followed by PD1 inhibitors (16). 
Our analysis shows that the time to onset may also be 
shorter with combination therapy when compared with 
monotherapy. The time to onset with monotherapy 
varies with the longest time interval to onset being 
27 weeks within our patient cohort. This highlights the 
need for continued vigilance throughout the treatment 
course. While in clinical trials (Supplementary Table 1) 
the predominant pattern of toxicity was hyperthyroidism 
transient thyroiditis has been previously identified (13, 
17); however, with regular patient sampling throughout 
treatment with ICIs, we have illustrated that the 
majority of patients actually experience the transient 
hyperthyroidism with the HH pattern, with only a 
minority of patients developing DN hypothyroidism as 
the initial manifestation of thyroid toxicity.
While the effector mechanisms responsible for the 
efficacy of ICIs are becoming better understood, the 
pathophysiological mechanisms underlying irAEs remain 
to be fully characterised. Previous data has shown that 
the thyrotoxic pattern is associated with increased 18FDG 
uptake compatible with an inflammatory process (18). It 
is possible that the threshold for developing autoimmune 
thyroid disease (AITD) varies in the population and that 
the use of ICIs lowers the threshold further allowing those 
who are most susceptible to develop thyroid dysfunction 
while undergoing therapy. Consistent with this, there is 
considerable similarity between the thyroid dysfunction 
associated with ICI use and painless thyroiditis (PT), 
a subtype of AITD (19, 20). The presentation can be 
variable; approximately 30% of patients manifest a 
triphasic pattern (hyper- followed by hypo- and then 
euthyroidism), while the remaining 70% manifest either 
the hyper- or hypo- phases in isolation prior to a return 
to euthyroidism (21, 22). In our patients, we did not see a 
return to euthyroidism, although that has been reported 
to occur in a minority of patients (23). The higher risk 
in women in our patients is consistent with the gender 
difference seen in painless thyroiditis. While baseline 
TSH does not appear predictive for ICI-induced thyroid 
dysfunction (12), it may be indicative of which pattern 
of dysfunction occurs, since those who developed DN 
in our series had significantly higher baseline TSH levels 
than those with the HH pattern. This suggests that 
some patients may have subclinical thyroid dysfunction 
at baseline which is then exacerbated by ICI therapy. 
Although we observed this in two patients (50%), we 
acknowledge that our sample size is small, and further 
studies to determine whether baseline TSH levels are 
truly predictive will need to be prospectively evaluated 
in a larger patient population. It is likely that both HH 
and DN patterns of thyroid dysfunction result from a 
degree of thyroiditis with glandular destruction; however, 
within the DN cohort, the degree of inflammation does 
not appear to lead to significant thyroxine discharge. 
The reasons for this are unclear at this stage but may 
be due to existing subclinical glandular insufficiency, 
lower absolute levels of inflammation or different 
inflammatory mediators.
In painless thyroiditis, it is known that patients 
have very high levels of anti-TPO antibodies (19). By 
contrast, we did not find a consistent pattern of thyroid 
autoantibodies in the patients on ICI with thyroid 
dysfunction. While Osorio et al. found that 8/10 patients 
in their cohort had positive thyroid autoantibodies (13), 
this has been less clear in other studies (12, 17). Our case 
series reinforces the fact that the mechanism of thyroid 
dysfunction is not clearly related to autoantibodies and 
alternative, probably cellular-mediated mechanisms 
may be responsible. It is possible that the presence of 
autoantibodies is more likely to be a secondary effect of 
thyroid destruction, possibly by T cells, although this will 
need further study using tissue sections.
In conclusion, we have characterised the course 
of patients who developed thyroid dysfunction after 
receiving ICIs either as monotherapy or in combination. 
Despite the limitation of this study being a single centre, 
retrospective review of a small number of patients, there 
was robust and standardised measurement of biochemical 
thyroid function allowing consistent characterisation. 
This illustrates that, unlike the apparent clinical picture 
reported in clinical trials (1, 2, 3, 4, 5, 6, 7, 8, 9, 10), the 
majority of patients develop a preceding hyperthyroidism 
prior to the hypothyroid phase. The levels of T4 can 
be significant but, despite this, treatment other than 
β-blockade for symptomatic control is not required. The 
hyperthyroid phase predictably self terminates with loss 
of thyroid capability. Furthermore, the natural course of 
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the thyroid dysfunction seems to be permanent. Larger, 
multicentre studies are needed to further validate these 
findings. Irrespective of further studies, it seems clear that 
patients should be monitored for thyroid dysfunction 
throughout their course of therapy because of the variable 
temporal relationship, so that symptomatic management 
of the hyperthyroid phase and timely institution of 
hormone replacement in the hypothyroid phase can be 
achieved, optimising symptomatic management and 
limiting the patient impact of thyroid irAEs.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0473.
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